type 2 diabetes, Novo Nordisk

Wegovy Maker Novo Nordisk Says New Pill Shows 14% Reduction in Heart Attacks, Strokes in Diabetic Patients
The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in patients by up to 14%, according to a new trial.
Novo Nordisk's oral diabetes drug cuts heart-related risks by 14% in study
Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study. The drug, Rybelsus, helped reduce the risk of these events,
Oral semaglutide cuts MACE risk by 14% in adults with type 2 diabetes: SOUL trial
According to new data from the SOUL trial Oral semaglutide reduced MACE by 14% in Type 2 Diabetes patients. Novo Nordisk will present more detailed data in 2025 and it intends to file for
Novo Nordisk: Oral Semaglutide Reduces Risk Of Cardiovascular Events In Phase 3 Trial
Novo Nordisk A/S (NVO) announced Monday the headline results from the SOUL cardiovascular outcomes trial, which achieved its primary
Novo Nordisk’s oral diabetes drug reduces heart-related risks by 14 percent
Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the year.
Novo Nordisk's GLP-1 pill reduces cardiovascular events by 14%
Discover how Novo Nordisk's GLP-1 medication, Rybelsus, reduces major adverse cardiovascular events by 14% in a phase 3 trial, with plans for an expanded label.
GlobalData on MSN11h
Novo Nordisk plans label expansion for Rybelsus following Phase III win
The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with T2D.
FiercePharma1d
Novo plots US, EU approval filings after oral semaglutide shows cardio benefits in certain diabetes patients
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...
Zacks.com on MSN6h
NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients
A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients ...
BioSpace1d
Novo Scores Late-Stage CV Win for Rybelsus on Heels of Wegovy Label Expansion
Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.
Novo Nordisk A/S (NVO): Most Promising Future Stock According to Analysts
We recently compiled a list of the 10 Most Promising Future Stocks According to Analysts. In this article, we are going to ...
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
How Much Does Semaglutide Cost With and Without Insurance?
You’ve probably heard of the semaglutide brand names Ozempic®, Wegovy, and Rybelsus. You may have even heard about affordable options like compounded semaglutide.
Novo's Rybelsus results may not be clinically meaningful, Bernstein says
Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major ...